Search clinical trials for: ABN401

Total 67 results

Abion Inc
Novotech (Australia) Pty Limited

Recruiting

To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation

Advanced Solid Tumors

Australia, Korea, Republic of
Abion Inc

Recruiting

To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

Advanced Solid Tumors

Korea, Republic of, Taiwan, United States
Yonsei University

Not yet recruiting

A Phase II Study of ABN401 in Advanced Solid Tumors With c-MET Gene Aberration

Neoplasms
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery

Recurrent Pancreatic Carcinoma | Stage IV Pancreatic Cancer | Recurrent Colorectal Carcinoma | Unresectable Solid Neoplasm | Metastatic Malignant Neoplasm in the Brain | Metastatic Solid Neoplasm | Recurrent Solid Neoplasm | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic... and other conditions

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery

Unspecified Adult Solid Tumor, Protocol Specific | Stage III Renal Cell Cancer | Recurrent Melanoma | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IV Melanoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Stage IIIA Melanoma | Stage IIIB Melanoma and other conditions

United States
Abion Inc

Completed

To Evaluate the Safety, Pharmacokinetic and the Effect of Food After Administration of ABN401 in Healthy Adult Volunteers

Solid Tumor

Korea, Republic of
invIOs GmbH

Recruiting

PBMC-based Leukocyte Immunotherapy (PALINDROM)

Advanced Solid Tumor

Austria
Eisai Co., Ltd.

Completed

A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Alzheimer's Disease

Japan
Novartis Pharmaceuticals

Completed

A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects

Hepatic Impairment

United States
Eisai Inc.

Completed

A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants

Healthy Volunteers

United States
Eisai Inc.

Completed

A Study of Subcutaneous Lecanemab in Healthy Participants

Healthy Volunteers

United States
Frontier Biotechnologies Inc.

Completed

A Study of a Topical Patch (AB001) in Patients With Chronic Low Back Pain

Chronic Low Back Pain

United States
Eisai Inc.
Biogen

Active, not recruiting

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease (Clarity AD)

Early Alzheimer's Disease

United States, Spain, Korea, Republic of, China, United Kingdom, Australia, Canada, France, Germany, Italy, Japan, Russian Federation, Singapore, Sweden
ABL Bio, Inc.

Recruiting

This is a Study to Evaluate the Safety, Tolerability, PK and PD of IV Administered ABL301 in Healthy Adult Participants

Healthy

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics Study of Asciminib in Subjects With Impaired Renal Function Compared to Matched Healthy Volunteers

Renal Impairment

Germany, Bulgaria
Accure Therapeutics
Simbec Research

Completed

BN201 SAD MAD Study in Healthy Subjects

Optic Neuritis | Optic; Neuritis, With Demyelination

United Kingdom
Washington University School of Medicine
Alzheimer's Association; Eisai Inc.

Not yet recruiting

DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease (DIAN-TU)

Dementia | Alzheimer's Disease | Alzheimer's Disease, Familial

United States, Australia, United Kingdom
Curon Biopharmaceutical (Australia) Co Pty Ltd
Novotech (Australia) Pty Limited

Terminated

A Study of CN1 in Combination With CN401 in Adult Patients With Relapsed/Refractory Lymphoid Malignancies

Relapsed Lymphoid Malignancies | Refractory Lymphoid Malignancies

Australia
Arcus Biosciences, Inc.

Completed

A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers (ARC-26)

Cancer

United Kingdom
Washington University School of Medicine
National Institute on Aging (NIA); Alzheimer's Association; Eisai Inc.; Accelerating...

Recruiting

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) (DIAN-TU)

Dementia | Alzheimers Disease | Alzheimers Disease, Familial

United States, Canada, Italy, Argentina, Australia, Colombia, Netherlands, Puerto Rico, Spain, United Kingdom, France, Ireland, Mexico, Brazil, Japan, Germany
Apeiron Biologics

Completed

Study of APN201 (Liposomal Recombinant Human Cu/Zn-Superoxide Dismutase) for the Prevention of Radiation-induced Dermatitis in Women With Breast Cancer

Radiation Induced Dermatitis

Austria
Novartis Pharmaceuticals

Active, not recruiting

Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation (AIM4CML)

Chronic Myelogenous Leukemia - Chronic Phase

United States
ABL Bio, Inc.
National OncoVenture

Completed

This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001

Advanced Solid Tumors

Korea, Republic of
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor

Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia

United States
Eisai Inc.
National Institute on Aging (NIA); Biogen; Alzheimer's Clinical Trials Consortium

Recruiting

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

Preclinical Alzheimer's Disease | Early Preclinical Alzheimer's Disease

United States, Singapore, Canada, Spain, Australia, Japan, United Kingdom, Sweden, Netherlands
Asana BioSciences

Terminated

Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer

Prostate Cancer | Cancer of the Prostate | Neoplasms, Prostate | Prostatic Cancer | Neoplasms, Prostatic | Prostate Neoplasms, Castration-resistant

United States
Apeiron Biologics

Completed

Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 (APN01-COVID-19)

COVID-19

Denmark, Germany, Austria, Russian Federation, United Kingdom
Augusta University
H. Jean Khoury Cure CML Consortium

Recruiting

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase (ALERTCML)

Leukemia, Myeloid | Chronic Myeloid Leukemia, Chronic Phase | Adult CML | Leukemia,Myeloid, Chronic

United States
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors

Leukemia, Chronic Myelogenous

China
BioNova Pharmaceuticals (Shanghai) LTD.

Terminated

Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Follicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma

China
Novartis Pharmaceuticals

Active, not recruiting

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP.

Chronic Myelogenous Leukemia

Spain, United Kingdom, Germany, Canada, Austria, France, Korea, Republic of, Greece, Singapore, Italy, Argentina, Poland, Vietnam, Malaysia, Oman, Brazil
Baxalta now part of Shire

Completed

Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901

Hemophilia A

United States, France, Austria, United Kingdom, Germany, Belgium, Canada, Italy, Sweden
Abbell AB

Completed

Clinical Trial of Topical ABL01 Treatment of Onychomycosis

Onychomycosis of Toenail

Sweden
Eisai Inc.

Completed

A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study

Alzheimer's Disease

United States
Eisai Inc.
Biogen

Active, not recruiting

A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease

Alzheimer's Disease

United States, Canada, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Spain, Sweden, United Kingdom
Wellstat Therapeutics

Approved for marketing

Uridine Triacetate as Antidote for Patients at Excess Risk of 5-FU Toxicity Due to Overdosage or Impaired Elimination

Toxicity Due to Chemotherapy
Novartis Pharmaceuticals

Completed

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Chronic Myelogenous Leukemia | Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Germany, Australia, Netherlands, Spain, Korea, Republic of, France, Japan, Italy, Singapore, United States
Frontier Biotechnologies Inc.

Completed

Tolerability, Safety and Pharmacokinetics of a Topical AB001 Patch in Healthy Subjects

Chronic Low Back Pain

China
Shire Regenerative Medicine, Inc.

Terminated

A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing

Epidermolysis Bullosa

United States, Spain, Austria, Canada, France, Germany, Poland, Portugal
Wellstat Therapeutics

Completed

Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria

Hereditary Orotic Aciduria

United States
Apeiron Biologics

Completed

Safety and Tolerability Study of APN01 (Recombinant Human Angiotensin Converting Enzyme 2)

Cardiovascular Diseases | Kidney Diseases | Pulmonary Diseases | Cancer Diseases

Switzerland
Novartis Pharmaceuticals

Available

Managed Access Programs for ABL001, Asciminib

Chronic Myeloid Leukemia in Chronic Phase
ABL Bio, Inc.

Recruiting

Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors

Advanced Solid Tumor

Korea, Republic of
Naryx Pharma

Completed

Evaluating SPRC-AB01 in Post-Surgical Subjects With Chronic Sinusitis

Chronic Sinusitis

United States
Novartis Pharmaceuticals

Recruiting

Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia (ASC2ESCALATE)

Chronic Myelogenous Leukemia - Chronic Phase

United States
Kyberg Vital GmbH

Completed

Dietary Intervention of Stress-Induced Neurovegetative Disorders With a Specific Amino Acid Composition (asn01) (asn01)

Nervous System Disorder | Imbalance of Constituents of Food Intake

Germany
Novartis Pharmaceuticals

Active, not recruiting

De-escalation and TFR Study in CML Patients Treated With Nilotinib Followed by a Second Attempt After Nilotinib and Asciminib Combination (DANTE)

Chronic Myeloid Leukemia

Italy
M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Recruiting

Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

Chronic Myeloid Leukemia

United States
BioNova Pharmaceuticals (Shanghai) LTD.

Completed

Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)

GVHD, Chronic

China
Bitop AG

Completed

Safety and Efficacy of Ectoin Allergy Nasal Spray and Ectoin Allergy Eye Drops in the Treatment of Seasonal Allergic Rhinitis (SAR) in Children and Adolescents

Seasonal Allergic Rhinitis | Seasonal Allergic Conjunctivitis

Germany

Search clinical trials for: ABN401

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations